Merck's Keytruda Shows Promise in Muscle-Invasive Bladder Cancer Trial
Merck's anti-PD-1 therapy, KEYTRUDA, has met the primary endpoint of disease-free survival (DFS) in a Phase 3 clinical trial for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma. The trial demonstrated a statistically significant and clinically meaningful improvement in DFS compared to observation after surgery. The safety profile of KEYTRUDA was consistent with previous studies, and results will be presented at an upcoming medical meeting and discussed with regulatory authorities.